Myeloma Intergroup MRD – ASH 2018 SGL Blogs

Using Minimal Residual Disease (MRD) in Clinical Practice

Jim Omel | November 30, 2018

Each year as ASH begins the Blood & Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup meets to improve treatment approaches related to transplantation in multiple myeloma. This group, representing all significant transplantation centers, discussed incorporating minimal residual disease (MRD) testing to better serve patients. These are some of the questions they reviewed. […]

How Do Patients Learn at ASH?

Jack Aiello | November 20, 2018

Soon I’ll be off to San Diego, the site of this year’s American Society of Hematology (ASH) conference. ASH is all about blood cancers (leukemia, lymphoma, multiple myeloma), and there are nearly 700 oral presentations and posters on myeloma alone. I’m so grateful to the International Myeloma Foundation (IMF) and their sponsors for sending me, […]